Ionis Pharmaceuticals (IONS) Sets New 1-Year High at $59.91

Ionis Pharmaceuticals Inc (NASDAQ:IONS) hit a new 52-week high on Tuesday . The company traded as high as $59.91 and last traded at $59.55, with a volume of 13485 shares changing hands. The stock had previously closed at $59.10.

A number of equities research analysts recently weighed in on IONS shares. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Leerink Swann started coverage on shares of Ionis Pharmaceuticals in a report on Tuesday, November 27th. They set a “market perform” rating and a $50.00 price objective for the company. Piper Jaffray Companies set a $50.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, November 6th. TheStreet upgraded shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, December 6th. Finally, Morgan Stanley set a $46.00 price target on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $54.25.

The company has a debt-to-equity ratio of 0.74, a quick ratio of 7.96 and a current ratio of 7.99. The firm has a market cap of $8.19 billion, a P/E ratio of 746.37 and a beta of 2.28.

In other news, COO Brett P. Monia sold 34,000 shares of the business’s stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $55.00, for a total value of $1,870,000.00. Following the completion of the sale, the chief operating officer now owns 49,841 shares in the company, valued at approximately $2,741,255. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Patrick R. O’neil sold 4,400 shares of the business’s stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $54.80, for a total transaction of $241,120.00. Following the completion of the sale, the senior vice president now owns 14,584 shares of the company’s stock, valued at approximately $799,203.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,290 shares of company stock valued at $4,020,635. Company insiders own 2.44% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Huntington National Bank raised its stake in shares of Ionis Pharmaceuticals by 159.3% during the 4th quarter. Huntington National Bank now owns 638 shares of the company’s stock worth $34,000 after acquiring an additional 392 shares in the last quarter. Essex Savings Bank bought a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $39,000. Laurel Wealth Advisors LLC bought a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $43,000. Daiwa Securities Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 29.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock worth $48,000 after acquiring an additional 200 shares in the last quarter. Finally, Portfolio Solutions LLC bought a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Ionis Pharmaceuticals (IONS) Sets New 1-Year High at $59.91” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2019/02/12/ionis-pharmaceuticals-ions-sets-new-1-year-high-at-59-91.html.

Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Featured Article: Tariff

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply